One major source of work has been IPOs from life-sciences and biotech companies. In December alone, gene-therapy company 4D Molecular Therapeutics, represented by Latham & Watkins, put its IPO legal fees at $1.9 million; Inhibikase Therapeutics, developing treatments for Parkinson's Disease, represented by Troutman Pepper Hamilton Sanders, set aside $1.9 million for lawyers; and AbCellera Biologics Inc., a Canadian biotech company working with Goodwin and Blake Cassels & Graydon that helps develop antibody-based therapies, put its fees at $4.5 million. Those numbers are according to the compa...